Oral semaglutide reduced blood sugar and weight when added to or switched from other incretin drugs, but was most effective in treatment-naive patients.
-0.85%HbA1c reduction in incretin-naive patients starting oral semaglutide
What the researchers found
Oral semaglutide reduced HbA1c by 0.85% in naive patients, 0.67% in DPP-4i switchers, and 0.13% in GLP-1 RA switchers.
Why it matters
Many patients switch between diabetes medications. Understanding how prior therapy affects oral semaglutide's effectiveness helps guide treatment decisions.
The numbers in context
- 368 participants with type 2 diabetes
- HbA1c change: naive group -0.85%, DPP-4 switch -0.67%, GLP-1 switch -0.13%
- DPP-4 and GLP-1 switch groups had significantly smaller HbA1c reductions vs naive (p significant)
- GLP-1 switch group lost less weight than naive group
- Dulaglutide-to-oral-semaglutide switch produced more weight loss than injectable-semaglutide-to-oral switch
How the study worked
Retrospective real-world analysis of 368 Japanese patients divided by prior incretin medication use.
Who was studied
N=368 Japanese adults with type 2 diabetes starting oral semaglutide. Grouped by prior medication: incretin-naive, DPP-4 inhibitor switch, or GLP-1 RA switch.
What this study cannot tell us
Retrospective study in Japanese patients; may not generalize. Relatively short 6-month follow-up. No randomization.
How to read the evidence
Retrospective real-world study. Moderate quality for effectiveness comparison but lacks randomization.
When this study was published
Published in 2025.
The bigger picture
As oral GLP-1 options expand, understanding the diminished returns when switching between similar drug classes will be important for sequencing therapy.
Questions still open
- Is switching from injectable to oral semaglutide justified for convenience despite reduced efficacy?
- Do longer follow-up periods show convergence of outcomes?
Common questions
Is oral semaglutide as effective as injectable semaglutide?
Should I switch from my current diabetes medication to oral semaglutide?
Read the original research
Effectiveness for adding or switching from other incretin-related drugs to oral semaglutide in type 2 diabetes.
Journal of diabetes investigation, 16(4), 608-614
Citation
Oya, Junko; Shimizu, Mika; Kubota, Ryo; Suda, Rika; Nagkagami, Tomoko. (2025). Effectiveness for adding or switching from other incretin-related drugs to oral semaglutide in type 2 diabetes.. Journal of diabetes investigation, 16(4), 608-614. https://doi.org/10.1111/jdi.14391